-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

Benzinga·07/28/2026 13:10:19
語音播報
Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.